Literature DB >> 15620435

Significance of IA-2 antibody in Japanese type 1 diabetes: its association with GAD antibody.

Tsuguhito Ota1, Toshinari Takamura, Yukihiro Nagai, Yukihiro Bando, Rika Usuda.   

Abstract

To investigate the presence and level of serum antibodies to IA-2 (IA-2A) in Japanese patients with adult type 1 diabetes in order to clarify its association with glutamic acid decarboxylase (GAD) antibody. Serum samples were obtained from 101 Japanese patients with type 1 diabetes, including 37 patients with slowly progressive form of type 1 diabetes. Serum levels of IA-2A and GADA were determined by radioimmunoassay. The study had a cross-sectional design. IA-2A and GADA were detected in 37 and 59% of these patients, respectively. Of the 37 slowly progressive form of patients, IA-2A and GADA were present in 49 and 86%, respectively (NS). GADA levels were significantly higher (P<0.05) in IA-2A positive than in IA-2A negative patients in slowly progressive form, but IA-2A levels did not differ significantly between GADA positive and GADA negative patients. Measuring IA-2A in combination with GADA is useful for the diagnosis and prognosis of type 1 diabetes in Japanese.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15620435     DOI: 10.1016/j.diabres.2004.05.004

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  2 in total

1.  Islet cell autoantibodies in African patients with Type 1 and Type 2 diabetes in Dar es Salaam Tanzania: a cross sectional study.

Authors:  J J K Lutale; H Thordarson; P I Holm; G E Eide; K Vetvik
Journal:  J Autoimmune Dis       Date:  2007-10-27

2.  Different interaction of onset age and duration of type 1 diabetes on the dynamics of autoantibodies to insulinoma-associated antigen-2 and zinc transporter 8.

Authors:  Eiji Kawasaki; Yoichi Oikawa; Akira Okada; Norio Kanatsuna; Tomoyuki Kawamura; Tadashi Kikuchi; Jungo Terasaki; Junnosuke Miura; Yoshihisa Itoh; Toshiaki Hanafusa
Journal:  J Diabetes Investig       Date:  2020-08-26       Impact factor: 4.232

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.